School of Medicine

The incidence of young-onset rectal cancer is increasing, and emerging evidence suggests younger patients have more aggressive disease. The standard of care for stage II and III rectal cancer includes neoadjuvant chemoradiotherapy followed by surgery and adjuvant chemotherapy. The purpose of this study was to determine whether response to neoadjuvant chemoradiotherapy differs in young-onset rectal cancer patients compared to older individuals.